CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma

Cancer

Volumn 79, Issue 9, 1997, Pages 1647-1655

  Yamamoto, Kohtarou ^a,b   Oka, Masaaki ^a   Hayashi, Hiroto ^a   Tangoku, Akira ^a   Gondo, Tosikazu ^a   Suzuki, Takashi ^a  

^a YAMAGUCHI UNIVERSITY   (Japan)

^b YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CYFRA 21 1; cytokeratin 19; esophageal squamous cell carcinoma; squamous cell carcinoma antigen; tumor marker

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN; CYTOKERATIN 19 FRAGMENT; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD LEVEL; CANCER CELL CULTURE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS CARCINOMA; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIODIAGNOSIS; SQUAMOUS CELL CARCINOMA;

EID: 0030910460     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970501)79:9<1647::AID-CNCR3>3.0.CO;2-9     Document Type: Article

References (25)

1. Katlic MR, Wilkins EW, Grillo HC. Three decades of treatment of esophageal squamous carcinoma at the Massachusetts General Hospital. J Thorac Cardiovas Surg l990;99:929-38.
2. Munck-Wikland E, Kuylenstirna R, Wahren B, Lindholm J, Haglund S. Tumor markers carcinoembryonic antigen, CA50, and CA 19-9 and squamous cell carcinoma of the esophagus. Cancer 1988;62:2281-6.
3. Ikeda K. Clinical and fundamental study of a squamous cell carcinoma related antigen (SCC-RA) for esophageal squamous cell carcinoma [in Japanese]. J Jpn Surg Soc 1990; 92:387-96.
4. Moll R, Franke WW, Schiller DL, Geiber B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982;31:11-24.
5. Debus E, Moll R, Franke WW, Weber K, Osborn M. Immunohistochemical distinction of human carcinomas by cytokeratin typing with monoclonal antibodies. Am J Pathol 1984; 114:121-30.
6. Moll R, Lowe A, Laufer J, Franke WW. Cytokeratin 20 in human carcinoma: a new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol 1992;140:427-47.
7. Broers JLV, Ramaekers FCS, Rot MK, Oostedorp T, Huysmans A, Van Muijen GNP, et al. Cytokeratins in different types of human lung cancer as monitored by chain-specific monoclonal antibodies. Cancer Res 1988;48:3221-9.
8. Stieber P, Hasholzner U, Bodenmuller H, Nagel D, Sunder-Plassmann L, Dienemann H, et al. A. CYFRA 21-1: a new marker in lung cancer. Cancer 1993;72:707-13.
9. Broers JLV, Klein Rot M, Oostedorp T, Huysmans A, Wagenaar SjSc, Wiersma-van Tilburg AJM, et al. Immunocytochemical detection of human lung cancer heterogeneity using antibodies to epithelial, neuronal and neuroendocrine antigens. Cancer Res 1987;47:3225-34.
10. Karsten U, Papsdorf G, Roloff G, Stolley P, Abel H, Walther I, et al. Monoclonal anti-cytokeratin antibody from a hybridoma clone generated by electrofusion. Eur J Cancer Clin Oncol 1985;21:733-40.
11. Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 1993;53:61-6.
12. Van der Gaast A, Schoenmakers CHH, Kok TC, Blijenberg BG, Cornillie F, Splinter TAW. Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1. Br J Cancer 1994;69:525-8.
13. Rastel D, Ramaioli A, Cornillie F, Thirion B, on behalf of the CYFRA 21-1 Multicentre Study Group. CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first-European multicentre evaluation. Eur J Cancer 1994;30:601-6.
14. Sugama Y, Kitamura S, Kawai T, Ohkubo A, Hasegawa S, Kuriyama T, et al. Clinical usefulness of CYFRA assay in diagnosing lung cancer: measurement of serum cytokeratin fragment. Jpn J Cancer Res 1994;85:1178-84.
15. Wieskopf B, Demangeat C, Purohit A, Stenger R, Gries P, Kreisman H, et al. Cyfra 21-1 as a biologic marker of non-small cell lung cancer: evaluation of sensitivity, specificity, and prognostic role. Chest 1995;108:163-9.
16. Wollenberg B, Ollesch A, Maag K, Funke I, Wilmes E. Micrometastases in bone marrow of patients with cancers in the head and neck area [in German]. Laryngorhinootologie 1994;73:88-93.
17. Moll R, Krepier R, Franke WW. Complex cytokeratin polypeptide patterns observed in certain human carcinomas. Differentiation 1983;23:256-69.
18. Oka M, Hirose K, Iizuka N, Aoyagi K, Yamamoto K, Abe T, et al. Cytokine mRNA expression patterns in human esophageal cancer cell lines. J Interferon Cytokine Res 1995;15:1005-9.
19. Hermanek P, Sobin LH, editors. TNM classification of malignant tumors. 4th edition. Genova: International Union Against Cancer, 1987.
20. Oka M, Yamammoto K, Takahashi M, Hakozaki M, Abe T, Iizuka N, et al. Relationship between serum levels of interleukin 6, various disease parameters, and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res 1996;56:2776-80.
21. Kato H, Suehiro Y, Morioka H, Torigoe T, Myoga A, Sekiguchi K, et al. Heterogeneous distribution of acidic TA-4 in cervical squamous cell carcinoma: immunohistochemical demonstration with monoclonal antibodies. Jpn J Cancer Res 1987;78:1246-50.
22. Michioka T, Takeshima N, Tsunaga N, Suminami Y, Nawata S, Kato H. Expression of squamous cell carcinoma antigen, a serine protease inhibitor, in the integument of vertebrates: possible role in stratification of epidermis. Acta Histochem Cytochem 1994;27:435-40.
23. Griner PF, Mayewski JR, Mushlin AI, Greenland P. Selection and interpretation of diagnostic tests and procedures: principles and applications. Ann Intern Med 1981;94:557-92.
24. Bates SE. Clinical applications of serum tumor markers. Ann Intern Med 1991;115:623-38.
25. Kato H, Torigoe T. Radioimmunoassay for tumor antigen of human squamous cell carcinoma. Cancer 1977;40:1621-8.